Major advances made in the clinical development of therapies to treat urinary and fecal incontinence.
Innovacell Biotechnologie AG, the Austrian biotechnology enterprise headquartered in Innsbruck, has increased its capital by three million Euros. "This will further drive the clinical development of our two products for the treatment of urinary and fecal incontinence," announced CEO Ekkehart Steinhuber.
Great progress was already being made in developments, stressed Steinhuber. "For ICES 13, the tissue therapy for the treatment of urinary stress incontinence, new data has emerged from a pharmaco-dynamic study. These findings support the effectiveness of the hypothesis," explained Steinhuber. By the end of the year, Innovacell expects to have the results of the phase III trial, currently underway.
Innovacell Biotechnologie AG is an enterprise largely financed with private equity; its joint shareholders are the Alpine Equity Management AG, the Fides Private Foundation, the Buschier AG and the management team. The managing board consists of Ekkehart Steinhuber and Rainer Mark Steiner. Innovacell employs 26 people and possesses one of the largest and most modern production facilities for the propagation of body tissue in Europe.
The company is engaged in the clinical development and marketing of autologous, minimally invasive cell therapies(using the patient's own cells), offering a potential cure with just one treatment ("once in a lifetime") that restores the function of the sphincter muscle in patients with urinary stress incontinence and involuntary stool loss.
Patients are now being recruited for the Phase II study of ICEF 15, the tissue therapy for targeted treatment of fecal incontinence. Said Steinhuber: "By the middle of the year we plan to have recruited all patients. Early results are expected in the first quarter of 2016."
Tel.: +43 (0)699 160 200 12
Tel +43 (0)512 - 563840
Fax +43 (0)512 - 563840-9